Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian P Tullius

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Advances in Experimental Medicine and Biology|June 3, 2020
Natural Killer Cell Immunotherapy for OsteosarcomaBrian P Tullius, Buhvana A Setty, Dean A Lee
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetiteAjay Gupta, Cenny Taslim, Brian P Tullius, et al.
Stem Cell Research & Therapy|March 26, 2021
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the futureMargaret G Lamb, Hemalatha G Rangarajan, Brian P Tullius, et al.
The Journal of Infection|February 7, 2021
COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patientsJennifer A Belsky, Brian P Tullius, Margaret G Lamb, et al.
Pediatric Blood & Cancer|May 1, 2019
Novel heterozygous mutation in the PTEN gene associated with ovarian germ cell tumor complicated by growing teratoma syndrome and overgrowth in a two-year-old femaleBrian P Tullius, Suma P Shankar, Stacey Cole, et al.
Frontiers in Oncology|April 22, 2022
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer ImmunotherapyEzgi Elmas, Noushin Saljoughian, Marcelo de Souza Fernandes Pereira, et al.
Pediatrics|October 25, 2018
Hospital-to-Home Interventions, Use, and Satisfaction: A Meta-analysisMichelle Y Hamline, Rebecca L Speier, Paul Dai Vu, et al.
Seminars in Hematology|December 1, 2020
Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activityMeisam Naeimi Kararoudi, Brian P Tullius, Nitin Chakravarti, et al.
Journal for Immunotherapy of Cancer|December 11, 2023
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodiesMd Faqrul Hasan, Amanda R Campbell, Tayler J Croom-Perez, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Advances in Experimental Medicine and Biology|June 3, 2020
Natural Killer Cell Immunotherapy for OsteosarcomaBrian P Tullius, Buhvana A Setty, Dean A Lee
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetiteAjay Gupta, Cenny Taslim, Brian P Tullius, et al.
Stem Cell Research & Therapy|March 26, 2021
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the futureMargaret G Lamb, Hemalatha G Rangarajan, Brian P Tullius, et al.
The Journal of Infection|February 7, 2021
COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patientsJennifer A Belsky, Brian P Tullius, Margaret G Lamb, et al.
Pediatric Blood & Cancer|May 1, 2019
Novel heterozygous mutation in the PTEN gene associated with ovarian germ cell tumor complicated by growing teratoma syndrome and overgrowth in a two-year-old femaleBrian P Tullius, Suma P Shankar, Stacey Cole, et al.
Frontiers in Oncology|April 22, 2022
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer ImmunotherapyEzgi Elmas, Noushin Saljoughian, Marcelo de Souza Fernandes Pereira, et al.
Pediatrics|October 25, 2018
Hospital-to-Home Interventions, Use, and Satisfaction: A Meta-analysisMichelle Y Hamline, Rebecca L Speier, Paul Dai Vu, et al.
Seminars in Hematology|December 1, 2020
Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activityMeisam Naeimi Kararoudi, Brian P Tullius, Nitin Chakravarti, et al.
Journal for Immunotherapy of Cancer|December 11, 2023
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodiesMd Faqrul Hasan, Amanda R Campbell, Tayler J Croom-Perez, et al.
Pageof 1